View By Speaker
M. Agronin, MD
M. Alexander, PhD, MA
S. Ancoli-Israel, Ph.D
L. Boesky, PhD
R. Brown, PhD
A. Burstein, MD
R. Dougherty, PhD
J. Draud, MD, MS
P. Earley
G. Emslie, MD
Larry Ereshefsky, PharmD
M. Forstein, MD
A. Frances, MD
M. Gold, MD
D. Goodman, MD
K. Gray, MD
D. Greenberg, MD
D. Greydanus, MD
R. Hendren, DO
R. Jackson, MD
R. Jain, MD, MPH
S. Jain, PsyD, LPC, MBA
J. Kane, MD
S. Katz, MSN PMH-CNS, BC
L. Kinsella, MD, FAAN
A. Krystal, MD
S. Levine, MD
J. Maldonado, MD
V. Maletic, MD, PA
B. McCarberg, MD
J. McGough, MD, MS
L. Miller, MD
L. Nagy, MD
H. Nasrallah, MD
S. Negi, MA, PhD
J. Nelson, MD
J. Newcomer, MD
G. Papakostas, MD
M. Piasecki, MD
J. Prince, MD
C. Raison, MD
P. Resnick, MD
A. Robb, MD
C. Rodgers, MD
M. Rosenberg, MD, PhD
J. Schim, MD
D. Schuyler, MD
S. Shea, MD
T. Simpatico, MD
T. Skale, MD
B. Smith, JD
T. Smith, MS Psych, PD, FASCP, LMHC, NCP
S. Sobel, MD
D. Sprague
M. Stein, MD, MPH
R. Stille, MBA
V. Strasburger, MD
J. Tsuang, MD
S. Verma, MD
J. Victoroff, MD, MA
J. Weiner, MD, PhD
S. Yaffe, MD
A. Young, MD, MSHS
|
Larry Ereshefsky, PharmDChief Scientific Officer, California Clinical Trials; VP, Principal Clinical Pharmacologist, and Psychiatric Therapeutic Expert, PAREXEL International; Clinical Professor, Psychiatry, University of Texas Health Science Center, San Antonio
| Thursday, November 5 07:45-09:00 a.m. |
413 - Dosage Formulation Technologies for Psychotropics: The Edge of the Pharmacokinetic-Pharmacodynamic Interface RX
1.25 credits - Room: Breakers EFKL |
Larry Ereshefsky, PharmD, Chief Scientific Officer, California Clinical Trials; VP, Principal Clinical Pharmacologist, and Psychiatric Therapeutic Expert, PAREXEL International; Clinical Professor, Psychiatry, University of Texas Health Science Center, San Antonio
|
Upon the completion of this activity, participants will be able to: - List Five Strategies to Modify Delivery of Medications;
- Explain what are the possible pharmacodynamic advantages, which result from dosage formulation related changes in drug concentrations at their sites of action;
- Identify future strategies for drug delivery and monitoring systems;
- Summarize data available supporting (or not) the advantages of novel dosage forms;
- Describe research strategies (and clinical approaches) to study the safety and efficacy of novel antipsychotic dosage forms.
|
| Thursday, November 5 09:15-10:30 a.m. |
426 - What Happened to Novel Development of Drugs To Treat Schizophrenia: Back to the Future? PD NP
1.25 credits - Room: Breakers EFKL |
Larry Ereshefsky, PharmD, Chief Scientific Officer, California Clinical Trials; VP, Principal Clinical Pharmacologist, and Psychiatric Therapeutic Expert, PAREXEL International; Clinical Professor, Psychiatry, University of Texas Health Science Center, San Antonio
|
Upon the compleion of this activiy, participants will be able to: - Describe the typical study design strategies used for the approval of a new antipsychotic in the United States and the European Union;
- List the newly approved (and not approved) medications for the treatment of schizophrenia, and how they differ from current therapies;
- Describe how the deconstruction of schizophrenia into endophenotypes and syndromes has stimulated a new generation of pharmacotherapeutic research and;
- List novel possible drug therapies that appear to work via glutamate/glycinergic.
|
|
